Spinal Stabilization Technologies

What Spinal Stabilization Technologies does

Spinal Stabilization Technologies, Ltd. is a privately held medical device company founded in 2010 by two interventional radiologists and headquartered in Kilkenny, Ireland, with a US presence in San Antonio. The company is developing the PerQdisc Nucleus Replacement System, a patented, motion-preserving lumbar intervertebral disc prosthesis designed to treat chronic discogenic low back pain associated with degenerative disc disease. The device consists of a dual-chamber implant — an outer membrane filled with an in-situ curing silicone polymer containing barium sulfate, and an inner chamber filled with radiopaque contrast media for visualization — that is delivered via a lateral transpsoas or retroperitoneal surgical approach using a small dilation into the annulus fibrosus. The technology is designed to replace only the diseased nucleus pulposus while preserving the annulus, endplates, and surrounding tissue, positioning PerQdisc as a less invasive alternative to spinal fusion or total disc replacement.

The company has no commercial revenue and operates in a clinical-trial-only regulatory posture. The PerQdisc system is investigational and not approved for sale in the United States or in regions accepting the CE Mark, though it received FDA Breakthrough Device Designation and the CE Mark in 2021. Spinal Stabilization Technologies has conducted an escalating series of clinical trials — N161 (2016), N181 (2018), LOPAIN1 (2021), LOPAIN2 (2022, South America), LOPAIN3 (2023, concurrent discectomy), and DISCPAIN1 (2025, US IDE) — across the United States, Latin America, Asia, and Eastern Europe, with the first US patient enrolled in March 2025. The company is led by President and CEO Mark Novotny, with a leadership team spanning R&D, operations, finance, and quality/regulatory functions.

Revenue generation is contingent on regulatory approvals. The intended commercial model is direct enterprise sales of the PerQdisc implant and its associated delivery system to hospitals and spine surgery centers for use by spinal surgeons in nucleus replacement procedures. Total disclosed funding is approximately $38.5 million, most recently a $17 million raise in 2025 to support the US IDE trial. The company does not yet have disclosed commercial pricing, distribution agreements, or hospital customers, and is sub-scale with 1-10 employees and no public revenue figures.

Name

Spinal Stabilization Technologies

Legal name

Spinal Stabilization Technologies, Ltd.

Website

https://sstspine.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

1–10 employees

Short description

Spinal Stabilization Technologies is a privately held Ireland-based medical device company developing the PerQdisc Nucleus Replacement System, an investigational motion-preserving lumbar disc prosthesis intended to treat chronic low back pain from degenerative disc disease via a minimally invasive lateral surgical approach.

Ownership category

akta.pro rank

Product category

Spinal Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Spine Implants & Motion Preservation (Fusion/Disc/Interspinous) (HLAHAEAC)

akta.pro secondary industry

Spine (Orthopedic Spine) (HLAKALAE)

Keywords

• Nucleus replacement implants
• Spinal medical devices
• Degenerative disc treatment
• Minimally invasive spine surgery
• Lumbar disc prosthesis

Headquarters

HQ city

San Antonio

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain

Revenue model

1. Medical Device Sales (Future): Once FDA and CE Mark approvals are obtained, the company plans to commercialize the PerQdisc Nucleus Replacement System. The device is currently investigational and not approved for sale in the United States or regions that accept CE Mark. Revenue will be generated through direct sales of the implant and associated delivery devices to hospitals and spine surgery centers.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Spinal Stabilization Technologies develops the PerQdisc Nucleus Replacement System, an in-situ formed silicone-based prosthesis for lumbar nucleus pulposus replacement. The system is designed as a motion-preserving, minimally invasive surgical alternative to spinal fusion and total disc replacement for patients with chronic discogenic low back pain caused by degenerative disc disease. The product is currently investigational, undergoing clinical trials in the US (IDE), Latin America, Asia, and Eastern Europe.

Product overview

Spinal Stabilization Technologies offers the PerQdisc™ Nucleus Replacement System as its core product, a motion-preserving surgical alternative to spinal fusion and total disc replacement for treating degenerative disc disease. The system includes the PerQdisc implant (a silicone-based prosthesis), the Disc Access System for surgical approach, and the Implant Delivery Device. The procedure is minimally invasive, requiring only a small dilation into the annulus fibrosus to access and replace the nucleus pulposus while preserving surrounding tissue.

Differentiator

Problem solved

Functional benefit

Brands

• PerQdisc™: Lumbar intervertebral disc nucleus replacement system designed to treat chronic low back pain associated with degenerative disc disease

Products and services

• PerQdisc Nucleus Replacement System A patented lumbar intervertebral disc nucleus replacement device made of an in-situ formed silicone-based prosthesis designed for patients suffering from chronic discogenic lumbar low back pain (dLBP) associated with degenerative disc disease (DDD). The device replaces the diseased nucleus pulposus to recreate physiological motion and redistribute weight-bearing forces. Includes dual chamber implant design with in-situ curing silicone polymer technology that creates a patient-specific, form-fitting custom implant.

Quantifiable outcome

• Procedure time expected to be approximately one hour
• +1 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators2 records

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• Medtronic Spine: Medtronic's Spine division offers the Bryan and Prestige cervical disc replacements and a broad lumbar portfolio including fusion and TDR. As the largest spine medtech player, it represents the dominant incumbent SST would compete against at launch.
• Aesculap Implant Systems: Aesculap (B. Braun) offers the activL Artificial Lumbar Disc and other lumbar motion-preservation products. As part of a large medical device conglomerate, it represents another incumbent competitor with established surgeon relationships and broader portfolios.
• Zimmer Biomet: Zimmer Biomet's Spine division (including the Mobi-C cervical disc) offers lumbar and cervical motion-preservation products. As a diversified orthopedic incumbent, it competes in the same procedural space and has far greater commercial scale than SST.
• Stryker Spine: Stryker's Spine division (acquired with Wright Medical and VertiFlex) offers a broad portfolio of lumbar and cervical solutions including the Mako Spine robotics platform. As a major diversified medtech incumbent, Stryker represents the scale and channel advantage SST lacks.

Direct peers

• NuVasive: NuVasive (now part of Globus Medical) developed the popular XL TDR and other lumbar motion-preservation devices. It directly competes with SST's nucleus replacement concept and represents the kind of established competitor SST would face upon commercialization.
• Centinel Spine: Centinel Spine specializes in motion-preservation spine technology, including the prodisc cervical and lumbar total disc replacement systems. They are a similar-sized, focused competitor in the motion-preservation space where SST's PerQdisc competes.
• Globus Medical: Globus Medical (now merged with NuVasive) is a leading spine implant company offering motion-preservation alternatives, total disc replacement, and fusion products. They compete directly with SST in the lumbar spine degenerative disc disease market with far greater scale and an established surgeon network.

Emerging players

• Premia Spine: Premia Spine developed the TOPS System, a posterior motion-preservation device for lumbar degenerative spondylolisthesis. As a similarly-sized company focused on motion-preservation, it represents a direct emerging competitor in the same clinical indication space.
• Spineart: Spineart is a privately-held spine technology company offering motion-preservation and fusion solutions globally. As a similarly-sized European-based peer with a similar focus on innovative spine solutions, it serves as a relevant comparable to SST.
• Orthofix Medical: Orthofix specializes in spine and orthopedic solutions including motion-preservation and biologics products. As a smaller publicly-traded peer, it is similar in scale ambition to SST and competes in overlapping degenerative disc disease treatment segments.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/spinal-stabilization-technologies-ltd

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds3 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Spinal Stabilization Technologies